ideagen cork report
DESCRIPTION
TRANSCRIPT
© DOLMEN 2010
Theme: Therapeutics –evolving and growing sector
Location: UCC, Western Gateway Building, CorkDate: Tuesday15th February 2011
© DOLMEN 2010
WH
O I
AM
Sean McNulty, MD Dolmen / INNOVATOR is a leading consultancy providing innovation management and design services to our clients in diverse markets.
© DOLMEN 2010
SPEAKERs
Mark Ledwidge, PhDFounder & VP Strategy, SolvotrinTherapeutics Ltd.
Christian Stafford, PhDSenior Commercialisation Specialist, Lifescience & Food Commercialisation Group ( EI Bio)Enterprise Ireland
© DOLMEN 2010
Team Idea Generation1. Ideas:
Idea gathering
Group Ideas
2. Develop Opportunities:
Map Opportunities
Select Opportunities
Share Opportunities
3. Business Feasibility:
Develop the Business potential
Rate your business feasibility!
© DOLMEN 2010
IDENTIFY CELLULAR ASSETS
TEAM 1
© DOLMEN 2010
Identify cellu
lar asse
ts
University ->
->marketin
g
•Cellular arrays
•Royalty
•IP legal
•Cost of patents and cell lines
•Cell banks
•Devils advocate
•Personalised med
Ger Fitz (Micro)
Brand
Benefits:
• University revenue generation
Co-cost of entry:
• Centralising through single conduit.
•International access.
•Primary Cells
•Toxicology
•Stream-lined decision time
•Commercialisation focus
•Preclinical
•Pre Ind
•Deposit bank of information
•Identification process
•Value
•Broadband in a box
•Product for sale
•Brand as commodity
•Linking into catelogues
•Marketing commodities
•Cell lines
© DOLMEN 2010
2. Opportu
nity
Mapping
TITLE: SILVERCELL
The ideas Describe the solution -
concept/system
What are the benefits?
Customer
Identify what is the target market?
Who is the customers? End users? Other
beneficiaries?
• Existing certified storage GLP
• Licensed by the IMB
• Facilitate the international
trade of cells and tissues.
• Direct link with Pharmacies.
• Create revenue for
Univeristies
• Make research sustainable
• In future Industry will require
safety and ….. On human tissue
and cells.
• Toxicity testing
-University revenue generation.
Cost efficient centralised
process. International single
brand.
- Toxicologists
- Pharma
- Dry discon.
© DOLMEN 2010
LINKSYN IN 51ST STATE
TEAM 2
© DOLMEN 2010
2. Opportunity Mapping
TITLE: LINKSYN IN 51st STATE
The ideas Describe the solution -
concept/system
What are the benefits?
Customer
Identify what is the target market?
Who is the customers? End users? Other
beneficiaries?• PROFILE TARGET MATCH
• NETWORK
• ‘Irish Mafia’ Techlink. Team of
experts
• BARE PIPELINE
• R&D
• NICHE EXPERTISE
• Id: decision makers, HQ
contacts
- FUNDING COLLABORATION.
MARKET ACCESS. JOBS. TAX.
-MNCs + SMEs.- HOW TO LEVERAGE LOCAL
FOOTPRINT BY DEVELOPING
LOCAL NETWORKS.
© DOLMEN 2010
Enhanced use of big Pharma + big
food + big medtech footprint in
Ireland for benefit of SMEs.
• How to leverage local footprint.
• Linksyn in the 51st State
•Customer decision makers.
• Unused IP
• License money
• What do SMEs need?
• Money market resources
• How not to get swallowed?
• Contacts to HQ
•Path to market
• Customer- an individual or a group within a …
• Value proposition
• Research Vs Development
• Niche expertise
• Networks: Bio, Pharma…
•What is in it for local MGR?
• Irish Mafia
• Profile multinationals
• Match company profile to your offering
• Incentives
• services supplied?
•Broaden pipeline
© DOLMEN 2010
SPIN DOCTORS
TEAM 3
© DOLMEN 2010
2. Opportunity Mapping
TITLE: SPIN DOCTORS
The ideas Describe the solution -
concept/system
What are the benefits?
Customer
Identify what is the target market?
Who is the customers? End users? Other
beneficiaries?• €5million fund
• 20 in 5
• market driven evaluation
• Early partner scouting
•Follow the money
• Business Partners
•Mentors
• R&D and production in
Ireland
• HQ in USA
• Experts
-Industry experts. Seed funding.
Right location. Money.
• PI Institution
• VC
• Big Pharma Foundations
Experts in therapeutics will lead
start-ups to success by following
the money from seed to
$millions to exit.
© DOLMEN 2010
1. A NEW MODEL FOR
THERAPEUTIC START-UP
• too much focus on start-up?
•Startup US license?
• When is the right time?
• What is a good idea?
• Market size >€1b
• People-lack of comm skills- sales/mk
• No VC infastructure
• €5m fund 2015
• Technology evaluation
• Follow the money
• Market driver- R&D!!!
•Scouting Partners early
• For Pharma
• Their needs, market size
• Data compatible with product roadmap
• sales force-IP/patient
•Niche
• Reg status
•For startup
•Source of funding
• Routes to market
• Business Plan
• Sale or partnership, (exit), timing
• Value of business/technology
•Reg status
2. PICK AND ‘LAND’ THE RIGHT
PARTNER
© DOLMEN 2010
NCTFC
TEAM 4
© DOLMEN 2010
2. Opportunity Mapping
TITLE: NCTFC National Clinical Trials Funding Corp
The ideas Describe the solution -
concept/system
What are the benefits?
Customer
Identify what is the target market?
Who is the customers? End users? Other
beneficiaries?
-Deliver Phase II trials in Ireland.
- Funding streams
-Health system
-Grow indigenous companies
• Pis
•Pharma
•Device
A new funding structure for
Clinical trials in Ireland.
© DOLMEN 2010
Make development (to
phase II) more efficient •I.T system
•Data management
•Pharma
•Device
• Specialist areas
•Sponsor (Directives)
•National Structure
•€250million
•HSE
•2% budget
•Regulatory Ethics
•CRO
•C.R.C’s
•Research nurses
•Revenue Streams
•Funding
•€5-10million
© DOLMEN 2010
Presentation of value propositions for selected opportunities.
TEAM Presentations
© DOLMEN 2010
What happens next
• Complete and return the participant follow up
sheet to your EI Regional Development Executive
• Join the IDEAGEN LinkedIn group http://www.linkedin.com/groups?gid=2649046&trk=hb_side_g
Keep up to date on latest from IDEAGEN by
• Following on Twitterhttp://twitter.com/ideagen
•Becoming a fan on Facebookhttp://www.facebook.com/pages/Ideagen/134045788401
